RGNX Investors Have Opportunity to Lead REGENXBIO Inc. Securities Fraud Lawsuit with the Schall Law Firm

Core Viewpoint - Investors in REGENXBIO Inc. have the opportunity to lead a securities fraud lawsuit against the company due to alleged misleading statements regarding the efficacy and safety of its product candidate RGX-111 [1] Group 1: Lawsuit Details - The Schall Law Firm is reminding investors of a class action lawsuit against REGENXBIO Inc. for violations of the Securities Exchange Act of 1934 [1] - The class period for the lawsuit is defined as between February 9, 2022, and January 27, 2026 [1] - Investors who suffered losses during this period are encouraged to contact the Schall Law Firm before April 14, 2026 [1] Group 2: Allegations Against the Company - The complaint alleges that REGENXBIO made false and misleading statements about RGX-111 while concealing negative data regarding its efficacy and safety [1] - A significant issue arose when an intraventricular CNS tumor was discovered in a participant treated in the RGX-111 study, which contradicted the company's positive statements [1] - The lawsuit claims that the company's public statements were materially misleading throughout the class period, leading to investor damages when the truth was revealed [1]